Global RNAi Medicine Market Growth (Status and Outlook) 2023-2029

Global RNAi Medicine Market Growth (Status and Outlook) 2023-2029

The global RNAi Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for RNAi Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for RNAi Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for RNAi Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key RNAi Medicine players cover Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Suzhou Ribo Life Science Co.,Ltd., Sirnaomics, GemmaPharma and RiboBio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “RNAi Medicine Industry Forecast” looks at past sales and reviews total world RNAi Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected RNAi Medicine sales for 2023 through 2029. With RNAi Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Medicine industry.

This Insight Report provides a comprehensive analysis of the global RNAi Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNAi Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNAi Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Medicine market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
siRNA
miRNA
piRNA
Others

Segmentation by application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Suzhou Ribo Life Science Co.,Ltd.
Sirnaomics
GemmaPharma
RiboBio

Please note: The report will take approximately 2 business days to prepare and deliver.